Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $1.8 million.

  • Tg Therapeutics' Gains from Sales and Divestitures fell 336.09% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 336.09%. This contributed to the annual value of $2.3 million for FY2024, which is 991.2% down from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Gains from Sales and Divestitures is $1.8 million, which was down 336.09% from $1.6 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Gains from Sales and Divestitures high stood at $6.3 million for Q4 2022, and its period low was $682840.0 during Q1 2021.
  • Over the past 5 years, Tg Therapeutics' median Gains from Sales and Divestitures value was $1.7 million (recorded in 2024), while the average stood at $2.0 million.
  • Per our database at Business Quant, Tg Therapeutics' Gains from Sales and Divestitures soared by 38298.31% in 2022 and then plummeted by 6026.28% in 2023.
  • Over the past 5 years, Tg Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $1.3 million in 2021, then surged by 382.98% to $6.3 million in 2022, then crashed by 60.26% to $2.5 million in 2023, then decreased by 9.91% to $2.3 million in 2024, then fell by 19.63% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.6 million for Q2 2025, and $1.4 million during Q1 2025.